TITLE

Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C

AUTHOR(S)
Reichen, Juerg
PUB. DATE
July 2002
SOURCE
ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main results; Conclusion.
ACCESSION #
8835510

 

Related Articles

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Interferon-α-2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C. Scott, L.J.; Perry, C.M. // Drugs;2002, Vol. 62 Issue 3, p507 

    Relatively few patients (≤20%) with chronic hepatitis C achieve a sustained virological response after interferon-α monotherapy. Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-α-2b have been investigated....

  • Interferon affacon-1.  // Formulary;May2005, Vol. 40 Issue 5, p168 

    Reports on successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin.

  • Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-a / Ribavirin. Caradonna, L.; Mastronardi, M.L.; Amati, L.; Magrone, T.; Cuppone, R.; Cozzolongo, R.; Manghisi, O.G.; Caccavo, D.; Amoroso, A.; Jirillo, E. // Current Pharmaceutical Design;May2002, Vol. 8 Issue 11, p981 

    The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-?)] have been demonstrated to mediate the antiviral immune response. Serum levels of...

  • Therapy of Chronic Hepatitis C: A Critical Review. Saracco, G.; Olivero, A.; Ciancio, A.; Carenzi, S.; Rizzetto, M. // Current Drug Targets - Infectious Disorders;Mar2003, Vol. 3 Issue 1, p25 

    Combination therapy (Interferon plus ribavirin) is the current therapeutic gold standard for naive Hepatitis C Virus (HCV)-positive patients and with the recent advent of pegylated (PEG) IFN the rate of the sustained virological response (HCV-RNA clearance 6 months after the end of treatment) is...

  • Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial. Adinolfi, L.E.; Utili, R.; Tonziello, A.; Ruggiero, G. // Gut;May2003, Vol. 52 Issue 5, p701 

    Background: Fifty per cent of chronic hepatitis C patients are non-responders to interferon. At present, there are no recommended therapeutic options for non- responders. Aims: The safety and long term effect of alpha interferon induction plus ribavirin with or without amantadine in the...

  • Interferon-α Alone versus Interferon-α plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-α Treatment. Tripi, S.; Di Gaetano, G.; Soresi, M.; Cartabellotta, F.; Vassallo, R.; Carroccio, A.; Anastasi, G.; Montalto, G. // BioDrugs;2000, Vol. 13 Issue 4, p299 

    Objective: To study the effects of monotherapy with leucocyte interferon-α (IFNα) versus IFNα + ribavirin in patients with chronic hepatitis C who were nonresponders to previous courses of recombinant or lymphoblastoid IFNα. Design and setting: This was a nonblind randomised study of...

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;10/20/2007, Issue 1174, p23 

    The article describes the case of a 42-year-old woman who developed diabetic ketoacidosis while receiving peginterferon-α-2b and ribavirin. The woman was receiving the medication because she has chronic hepatitis C. The symptoms presented by the patients 2 months after receiving the regimen...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics